The acquisition, announced on 21 December 2010, is the first major acquisition by DSM after its successful transformation into a Life Sciences and Materials Sciences company.
The acquisition, for a total consideration of about €790m, is fully in line with DSM’s strategy for its nutrition cluster (‘continued value growth’) and adds a new growth platform for healthy and natural food ingredients for infant formula and other food and beverage applications, especially focused on Polyunsaturated Fatty Acids (PUFAs) such as microbial omega-3 DHA (docosahexaenoic acid) and omega-6 ARA (arachidonic acid).
Planning for the integration of DSM and Martek started when the deal was first announced in December, and now a full-scale integration of the two businesses will begin.
A dedicated integration team consisting of DSM and Martek representatives will work to assess the best way to combine the two organisations.
Source: DSM
© FoodBev Media Ltd 2024